ClinicalTrials.gg
RecruitingNCT07684599Updated Nov 3, 2026

A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

A Phase 3 interventional study of Mocertatug rezetecan and Dostarlimab in Neoplasms, Endometrial, sponsored by GlaxoSmithKline. Recruiting at 12 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 3, 2026Now RecruitingFirst sites in Japan, Canada and South Korea+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
610
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Endometrial Neoplasms by GlaxoSmithKline — 7 open to participants now, 10 under way, 3 of them phase 3. Endometrial Neoplasms · GlaxoSmithKline.

Planned enrollment
Largest of 13
610 · median 100
Started
2026
with 3 others
Phase 3
3 of 13
3 open now
Registered
12th of 13
by date

Among the 13 studies in Endometrial Neoplasms by GlaxoSmithKline, this one has the largest planned enrollment, is one of 4 that started in 2026, is one of 3 in phase 3, and was the 12th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

7 of the 13 studies in Endometrial Neoplasms by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Endometrial Neoplasms by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to see how well mocertatug rezetecan (Mo-Rez) in combination with physician's choice of immunotherapy (dostarlimab or pembrolizumab) works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared with the physician's choice of immunotherapy (dostarlimab or pembrolizumab) alone, which represents the current standard of care. The study will also assess whether the drug combination is safe and tolerated well by participants compared to standard of care and will help us better understand its impact on Health-Related Quality of Life of participants.

03

Conditions studied

  • Neoplasms, Endometrial

Keywords

  • Mocertatug rezetecan
  • Mo-Rez
  • GSK5733584
  • Dostarlimab
  • Pembrolizumab
  • Endometrial Cancer
  • Antibody-Drug Conjugate
  • BEHOLD-Endometrial02
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the form (ICF).
  • Has received 6 cycles of therapy (i.e. induction therapy), consisting of platinum-based doublet chemotherapy (e.g., carboplatin/paclitaxel) with immune checkpoint inhibition as part of standard of care (either pembrolizumab or dostarlimab) or via trial Run-In (dostarlimab). Receipt of only 4 cycles of chemotherapy is permitted if chemotherapy was discontinued due to toxicity, provided that the participant received at least 12 weeks of therapy during the induction period.
  • Is able to commence C1D1 of study treatment within 3 - 9 weeks of the final dose of first-line therapy.
  • Is deemed suitable to continue with maintenance therapy with immune checkpoint inhibition (dostarlimab or pembrolizumab).
  • Demonstrates no clinical or radiographic progression of disease per investigator after the final dose of induction therapy. Final dose is defined as the last day that either platinum chemotherapy, taxane chemotherapy or immune checkpoint inhibition was given within the last cycle of induction therapy
  • Has confirmed endometrial carcinoma including but not limited to endometrioid, serous, clear cell and endometrial carcinosarcoma. Mixed epithelial carcinomas are permitted.
  • Meets one of the following criteria:

    • Has newly diagnosed stage III disease [2023 International Federation of Gynecology and Obstetrics (FIGO) staging] with measurable residual disease >1 cm after primary debulking surgery (incomplete cytoreduction).
    • Has newly diagnosed stage III disease (2023 FIGO staging) that is not suitable for primary debulking surgery with .
    • Has newly diagnosed stage IV disease (2023 FIGO staging) and any residual disease status (measurable or non-measurable) following debulking surgery. Participants not suitable for primary debulking surgery are also permitted.
    • Has recurrent disease and is naïve to systemic anticancer therapy and any disease status (measurable or non-measurable).
    • Has recurrent disease after receiving prior /adjuvant systemic anticancer therapy and had a recurrence >12 months after last dose of neo-adjuvant/adjuvant treatment. Participants with any disease status (measurable or non-measurable) are permitted.
  • Has a tumor demonstrating either Mismatch Repair proficient (MMRp) or Microsatellite stable (MSS).
  • Has provided a Formalin fixed, paraffin embedded (FFPE) tumor tissue sample sufficient for the central assessment of B7 homolog 4 protein (B7-H4) expression and MMR (if local MMRp/MSS test result(s) not available), with the result of B7-H4 expression testing available prior to date of randomization.
  • Is willing to use adequate . Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Has an (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Mesenchymal tumors of the uterus (uterine sarcomas) and neuroendocrine uterine cancer.
  • Has a (except disease under study) that has progressed or required active treatment within 36 months prior to date of randomization except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas.
  • Any evidence of current Interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or non-infectious pneumonitis.
  • Has experienced any of the following with prior immunotherapy: any imAE ≥ Grade 3, immune-mediated severe neurologic events of any grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain-Barré Syndrome, or transverse myelitis), exfoliative dermatitis of any grade (Stevens-Johnson syndrome [SJS], Toxic Epidermal Necrolysis [TEN], or Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS] syndrome, or myocarditis of any grade.
  • Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to ≤ Grade 1 or to the baseline status preceding prior therapy, excluding alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy, or adverse reactions that the investigator, with the agreement of the sponsor, considers to be not for the tolerability of study intervention in the current clinical study.
  • Has had any major surgery within 28 days prior to date of C1D1 or received focal radiotherapy within 21 days prior to date of C1D1.
  • Has received treatment with an agent within 30 days prior to C1D1.
  • Has received prior therapy with topoisomerase I inhibitors (e.g. irinotecan or topotecan) or Antibody-Drug Conjugate (ADC)with a topoisomerase I inhibitor warhead, B7-H4 targeted therapy, or .
  • Has received treatment with inhibitors of P-glycoprotein (P-gp) or Breast cancer resistant protein (BCRP), or OATP1B1/1B3 transporterswithin 7 days prior to the date of C1D1. Inducers of P-gp should be discontinued for at least 14 days prior to the date of C1D1.
  • Has received any transfusion of blood products (including or red blood cells) or administration of colony-stimulating factors (including Granulocyte-Colony Stimulating Factor [G-CSF], Granulocyte-Macrophage Colony-Stimulating Factor [GM-CSF], or recombinant erythropoietin) within 14 days prior to C1D1.
  • Has an (ALT) value >2.5 × (ULN) or for participants with documented liver /tumor infiltration has an ALT value >5 × ULN.
  • Has a total value >1.5 × ULN.
  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice. Participants who exhibit these signs or symptoms as a result of the malignancy under investigation and whose conditions are deemed adequately controlled by the investigator may be eligible for inclusion.
  • Has interval (QTc) >470 milliseconds (msec).
  • Has a history of symptomatic pericarditis of any cause within 6 months prior to screening or evidence of cardiac abnormalities within 12 months prior to screening such as serious, uncontrolled cardiac arrhythmia or clinically significant abnormalities.
  • Has any active renal condition (e.g., infection, requirement for dialysis, or any other significant renal condition that could affect the participant's safety).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
610 participants (estimated)

Study arms

  • Experimental
    Mocertatug rezetecan plus physician's choice of immunotherapy (dostarlimab or pembrolizumab)

    Participants will receive Mocertatug rezetecan along with physician's choice of immunotherapy (Dostarlimab or Pembrolizumab)

    Drug: Mocertatug rezetecan · Drug: Dostarlimab · Drug: Pembrolizumab

  • Active comparator
    Physician's choice of immunotherapy (dostarlimab or pembrolizumab)

    Participants will receive physician's choice of immunotherapy (Dostarlimab or Pembrolizumab alone)

    Drug: Dostarlimab · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) by BICR assessment

    PFS is defined as the time from the date of randomization to the date of first documented Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by Blinded independent central review (BICR) assessment or death from any cause, whichever occurs first

    Time frame: Up to approximately 143 weeks

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause

    Time frame: Up to approximately 260 weeks

  2. PFS by investigator assessment

    PFS is defined as the time from the date of randomization to the date of first documented PD per RECIST 1.1 by investigator assessment or death from any cause, whichever occurs first

    Time frame: Up to approximately 143 weeks

  3. Objective response rate (ORR) by investigator assessment

    ORR is defined as the percentage of participants with best overall response of either complete response (CR) or partial response (PR) per RECIST 1.1 by investigator assessment

    Time frame: Up to approximately 260 weeks

  4. ORR by BICR assessment

    ORR is defined as the percentage of participants with best overall response of either CR or PR per RECIST 1.1 by BICR assessment

    Time frame: Up to approximately 260 weeks

  5. Duration of Response (DOR) by investigator assessment

    DOR is defined as the time from the date of first documented objective response (CR or PR) to the date of first documented PD per RECIST 1.1 by investigator assessment or death from any cause, whichever comes first

    Time frame: Up to approximately 260 weeks

  6. DOR by BICR assessment

    DOR is defined as the time from the date of first documented objective response (CR or PR) to the date of first documented PD per RECIST 1.1 by BICR assessment or death from any cause, whichever comes first

    Time frame: Up to approximately 260 weeks

  7. Progression Free Survival on subsequent line of therapy (PFS2)

    PFS2 is defined as the time from the date of randomization to the date of first documented investigator-assessed clinical or radiographical progression following the first subsequent anticancer therapy and after the progression event used for PFS, or death from any cause, whichever occurs first

    Time frame: Up to approximately 260 weeks

  8. Time to first subsequent therapy or death (TFST)

    TFST is defined as the time from the date of randomization to the date of initiation of subsequent therapy or death from any cause, whichever occurs first

    Time frame: Up to approximately 260 weeks

  9. Time to second subsequent therapy (TSST)

    TSST is defined as the time from the date of randomization to the date of initiation of second subsequent therapy or death from any cause, whichever occurs first

    Time frame: Up to approximately 260 weeks

  10. Serum pharmacokinetic (PK) concentration of Mo-Rez (conjugated antibody and payload)

    Time frame: Up to approximately 260 weeks

  11. Number of participants with Antidrug antibody (ADA) or Neutralizing Antibody (NAb) against Mo-Rez

    Time frame: Up to approximately 260 weeks

  12. Titers of ADA against Mo-Rez

    Time frame: Up to approximately 260 weeks

  13. Number of participants with Treatment-emergent adverse event (TEAEs), Adverse event of special interest (AESIs), Immune-mediated adverse event (imAEs) and Treatment-emergent serious adverse event (TESAEs)

    Time frame: Up to approximately 260 weeks

  14. Number of participants with TEAEs leading to dose modifications or study intervention discontinuation

    Time frame: Up to approximately 260 weeks

  15. Number of participants with changes in vital signs, laboratory tests (hematology and clinical chemistry), and Electrocardiogram (ECG)

    Time frame: Up to approximately 260 weeks

  16. Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) score

    The EORTC QLQ-C30 includes 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. Participants responses on these items are averaged and then transformed to scores ranging from 0 to 100. For items related to function and global health status, a higher score indicates better functioning or a better overall state of health, while, for symptom-related items, a higher score denotes more severe symptoms.

    Time frame: Up to approximately 260 weeks

  17. Change from baseline in EORTC QLQ- Endometrial Cancer Module (EN24) score

    The EORTC QLQ-EN24 includes a 24-item questionnaire for evaluating endometrial cancer-specific symptoms and concerns in participants of cancer clinical studies. Participants responses are averaged and then transformed to a score ranging from 0 to 100. For functional and global health items, a higher score indicates better functioning or a better overall state of health, while for symptom items, a higher score indicates more severe symptoms.

    Time frame: Up to approximately 260 weeks

  18. Time to deterioration (TTD) of EORTC QLQ-EN24

    TTD is defined as the time from date of randomization to the first confirmed clinically meaningful deterioration on any of the domains of EORTC QLQ-EN24: lymphoedema, urological symptoms, gastrointestinal symptoms, and pain in back and pelvis

    Time frame: Up to approximately 260 weeks

  19. TTD of EORTC QLQ-C30

    TTD is defined as the time from date of randomization to the first confirmed clinically meaningful deterioration on any of the domains of EORTC QLQ-C30: physical functioning, role functioning, and Global Health Status (GHS) /Quality of Life (QoL)

    Time frame: Up to approximately 260 weeks

07

Study locations

12 of 12 sites recruiting
  • GSK Investigational Site
    Toronto, Ontario M5G 1X6, Canada
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H4A 0B1, Canada
    Recruiting
  • GSK Investigational Site
    Fukuoka, 812-8582, Japan
    Recruiting
  • GSK Investigational Site
    Fukushima, 960-1295, Japan
    Recruiting
  • GSK Investigational Site
    Hokkaido, 060-8648, Japan
    Recruiting
  • GSK Investigational Site
    Ibaraki, 305-8576, Japan
    Recruiting
  • GSK Investigational Site
    Miyagi, 980-8574, Japan
    Recruiting
  • GSK Investigational Site
    Numakunai, 028-3695, Japan
    Recruiting
  • GSK Investigational Site
    Osaka, 569-8686, Japan
    Recruiting
  • GSK Investigational Site
    Saitama, 350-1298, Japan
    Recruiting
  • GSK Investigational Site
    Tokyo, 135-8550, Japan
    Recruiting
  • GSK Investigational Site
    Daegu, 700-712, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2029, 33 months after the start.

Of 44 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's planned 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 6, 2026
StartActual
Sep 24, 2026
Primary completionEst.
Jul 23, 2029
CompletionEst.
Sep 18, 2031
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
12 sites added — first sites in Japan, Canada and South Korea
Show 12 added (9 Japan, 2 Canada, 1 South Korea)
  • GSK Investigational Site · Fukuoka, Japan
  • GSK Investigational Site · Fukushima, Japan
  • GSK Investigational Site · Hokkaido, Japan
  • GSK Investigational Site · Miyagi, Japan
  • GSK Investigational Site · Numakunai, Japan
  • GSK Investigational Site · Osaka, Japan
  • GSK Investigational Site · Saitama, Japan
  • GSK Investigational Site · Tokyo, Japan
  • GSK Investigational Site · Toronto, Canada
  • GSK Investigational Site · Montreal, Canada
  • GSK Investigational Site · Ibaraki, Japan
  • GSK Investigational Site · Daegu, South Korea
across 2 updates, Oct 15, 2026 – Nov 3, 2026
Start date
Sep 3, 2026→Sep 24, 2026 (actual)
Oct 15, 2026
Show all 2 updates
  1. Nov 3, 2026
    4 sites added — first sites in Canada and South Korea
    Show 4 added (2 Canada, 1 Japan, 1 South Korea)
    • GSK Investigational Site · Toronto, Canada
    • GSK Investigational Site · Montreal, Canada
    • GSK Investigational Site · Ibaraki, Japan
    • GSK Investigational Site · Daegu, South Korea
  2. Oct 15, 2026
    Not yet recruiting→Recruiting
    8 sites added — first site in Japan
    Show 8 added (8 Japan)
    • GSK Investigational Site · Fukuoka, Japan
    • GSK Investigational Site · Fukushima, Japan
    • GSK Investigational Site · Hokkaido, Japan
    • GSK Investigational Site · Miyagi, Japan
    • GSK Investigational Site · Numakunai, Japan
    • GSK Investigational Site · Osaka, Japan
    • GSK Investigational Site · Saitama, Japan
    • GSK Investigational Site · Tokyo, Japan
    Start date Sep 3, 2026→Sep 24, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07684599
Lead sponsor
GlaxoSmithKline
Collaborators
ENGOT, GOG, APGOT
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Sep 24, 2026
Primary completion
Jul 23, 2029 (estimated)
Completion
Sep 18, 2031 (estimated)
Last update
Nov 3, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mocertatug rezetecan

Start the discussion